Activated PI3K/Akt/mTOR pathway is a uniform finding in cancer, including hematologic malignancies,29,30 whereas its significance in oncogenesis is highlighted by the plethora of inhibitors (dual PI3K–mTOR inhibitors, PI3K inhibitors, Akt inhibitors and mTOR inhibitors) that are in clinical development for the treatment of cancer, with promising results in hematologic malignancies.30–32. Here, AKT1 is linked to hematologic disorder.